HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant

Summary

The purpose of this study is to determine whether patients treated for chronic hepatitis C (HCV) with zepatier (grazoprevir/elbasvir) prior to kidney transplant will have a stronger immune response compared to patients treated after kidney transplant. 25 patients with chronic kidney disease (CKD) and HCV will be treated with zepatier and 25 kidney transplant recipients with chronic kidney disease will be treated with zepatier. Blood markers of immune function will be monitored in both groups to determine their response to therapy.

Timeline

Start

2017-05-01

Primary completion

2021-09-01

Completion

2022-06-08

Drugs

Indications